Cochrane · systematic review · CD011094
Omega‐6 fats for the primary and secondary prevention of cardiovascular disease
Hooper, L, Al‐Khudairy, L, Abdelhamid, AS, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
13
current version
GRADE rated
13
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 5 · 38.5%Low 6 · 46.2%Moderate 1 · 7.7%High 1 · 7.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyHigher versus lower omega‐6: primary outcomes
Population: adults with or without existing CVD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Study duration range 12‐96 months Omega‐6 dose range 1.5%‐24.5% E Higher vs lower omega‐6: primary outcomes | RR 1 [0.88, 1.12] | 10 studies · 4506 participants | Low |
Cardiovascular mortality Study duration range 24‐96 months Omega‐6 dose range 2.8%‐24.5% E Higher vs lower omega‐6: primary outcomes | RR 1.09 [0.76, 1.55] | 7 studies · 4019 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Cardiovascular events: any Study duration range 12‐96 months Omega‐6 dose range 2.8%‐24.5% E Higher vs lower omega‐6: primary outcomes | RR 0.97 [0.81, 1.15] | 7 studies · 4962 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
CHD events: myocardial infarction (fatal or non‐fatal) or angina Study duration range 12‐96 months Omega‐6 dose range 2.8%‐24.5% E Higher vs lower omega‐6: primary outcomes | RR 0.88 [0.66, 1.17] | 7 studies · 3997 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
MACCEs Study duration range 24‐96 months Omega‐6 dose range 2.8%‐12.0% E Higher vs lower omega‐6: primary outcomes | RR 0.84 [0.59, 1.2] | 2 studies · 2879 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Stroke: fatal or non‐fatal Study duration range 24‐96 months Omega‐6 dose range 2.8%‐21.9% E Higher vs lower omega‐6: primary outcomes | RR 1.36 [0.45, 4.11] | 4 studies · 3730 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Higher versus lower omega‐6: additional key outcomes
Population: adults with or without existing CVD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
MI Study duration range 12‐96 months Omega‐6 dose range 2.8%‐24.5% E Higher vs lower omega‐6: additional key outcomes | RR 0.88 [0.76, 1.02] | 7 studies · 4606 participants | Low |
Serum TC Study duration range 12‐96 months Omega‐6 dose range 2.0%‐24.5% E Higher vs lower omega‐6: additional key outcomes | no estimate extracted | 10 studies · 4280 participants | High |
Serum TG Study duration range 12‐72 months Omega‐6 dose range 2.0%‐15.0% E Higher vs lower omega‐6: additional key outcomes | no estimate extracted | 5 studies · 834 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
LDL Study duration range 12‐24 months Omega‐6 dose range 2.0%‐15.0% E Higher vs lower omega‐6: additional key outcomes | no estimate extracted | 2 studies · 244 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
HDL Study duration range 12‐24 months Omega‐6 dose range 2.0%‐15.0% E Higher vs lower omega‐6: additional key outcomes | no estimate extracted | 4 studies · 1995 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Body weight (kg) Study duration range 12‐48 months Omega‐6 dose range 0.8%‐2.8% E Higher vs lower omega‐6: additional key outcomes | no estimate extracted | 4 studies · 358 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
BMI Study duration 51 months Omega‐6 dose 6.6% E Higher vs lower omega‐6: additional key outcomes | no estimate extracted | 1 study · 371 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Higher versus lower omega‐6: primary outcomes
Population: adults with or without existing CVD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Study duration range 12‐96 months Omega‐6 dose range 1.5%‐24.5% E Higher vs lower omega‐6: primary outcomes | RR 1 [0.88, 1.12] | 10 studies · 4506 participants | Low |
Cardiovascular mortality Study duration range 24‐96 months Omega‐6 dose range 2.8%‐24.5% E Higher vs lower omega‐6: primary outcomes | RR 1.09 [0.76, 1.55] | 7 studies · 4019 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Cardiovascular events: any Study duration range 12‐96 months Omega‐6 dose range 2.8%‐24.5% E Higher vs lower omega‐6: primary outcomes | RR 0.97 [0.81, 1.15] | 7 studies · 4962 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
CHD events: myocardial infarction (fatal or non‐fatal) or angina Study duration range 12‐96 months Omega‐6 dose range 2.8%‐24.5% E Higher vs lower omega‐6: primary outcomes | RR 0.88 [0.66, 1.17] | 7 studies · 3997 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
MACCEs Study duration range 24‐96 months Omega‐6 dose range 2.8%‐12.0% E Higher vs lower omega‐6: primary outcomes | RR 0.84 [0.59, 1.2] | 2 studies · 2879 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Stroke: fatal or non‐fatal Study duration range 24‐96 months Omega‐6 dose range 2.8%‐21.9% E Higher vs lower omega‐6: primary outcomes | RR 1.36 [0.45, 4.11] | 4 studies · 3730 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Higher versus lower omega‐6: additional key outcomes
Population: adults with or without existing CVD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
MI Study duration range 12‐96 months Omega‐6 dose range 2.8%‐24.5% E Higher vs lower omega‐6: additional key outcomes | RR 0.88 [0.76, 1.02] | 7 studies · 4606 participants | Low |
Serum TC Study duration range 12‐96 months Omega‐6 dose range 2.0%‐24.5% E Higher vs lower omega‐6: additional key outcomes | no estimate extracted | 10 studies · 4280 participants | High |
Serum TG Study duration range 12‐72 months Omega‐6 dose range 2.0%‐15.0% E Higher vs lower omega‐6: additional key outcomes | no estimate extracted | 5 studies · 834 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
LDL Study duration range 12‐24 months Omega‐6 dose range 2.0%‐15.0% E Higher vs lower omega‐6: additional key outcomes | no estimate extracted | 2 studies · 244 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
HDL Study duration range 12‐24 months Omega‐6 dose range 2.0%‐15.0% E Higher vs lower omega‐6: additional key outcomes | no estimate extracted | 4 studies · 1995 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Body weight (kg) Study duration range 12‐48 months Omega‐6 dose range 0.8%‐2.8% E Higher vs lower omega‐6: additional key outcomes | no estimate extracted | 4 studies · 358 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
BMI Study duration 51 months Omega‐6 dose 6.6% E Higher vs lower omega‐6: additional key outcomes | no estimate extracted | 1 study · 371 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |